Korean biotech developing bispecific antibodies for cancer and neurodegenerative disease, licensed to global partners including Sanofi.
Korean biotech developing bispecific antibodies for cancer and neurodegenerative disease, licensed to global partners including Sanofi.
Earns from upfront and milestone payments in licence deals rather than product sales, so income arrives in large, uneven amounts tied to partners' trial progress. The Grabody platform, which carries drugs across the blood-brain barrier, is the technology partners pay for.
Moat: narrow (IP / patents). Proprietary bispecific antibody platform validated by large global pharma licensing deals.
Headquarters: Seongnam, South Korea · Founded: 2011 · Employees: 108
Size ABL Bio (298380.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.51B, the 170th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩36,000 on 18 Nov 2026.
Performance Over six months the shares fell 71.3%, against -8.4% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue fell 53.0% over the last twelve months (peer median +10.1%); the operating margin is -201.0% (peer median 11.0%).
Valuation It trades at 46.5× enterprise value to sales against a peer median of 3.8× (3rd most expensive of 20).
Capital Return on invested capital runs 84.5 points below its cost of capital (5.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩41.6B | ₩79.3B | ₩33.4B | ₩65.5B | ₩67.3B |
| Revenue growth | — | +138% | -49% | -3% | — |
| Gross profit | ₩5.88B | ₩45.9B | ₩11.3B | ₩41.4B | ₩45.6B |
| EBITDA | -₩79.6B | -₩36.9B | -₩57.0B | -₩27.3M | ₩3.23B |
| Net income | -₩81.9B | -₩37.8B | -₩55.5B | -₩2.65B | ₩3.21B |
| Free cash flow | -₩45.4B | -₩61.3B | -₩78.4B | -₩34.1B | ₩68.8B |
| Capital expenditure | ₩4.24B | ₩20.7B | ₩9.06B | ₩5.84B | ₩3.64B |
| Total debt | ₩55.4B | ₩55.3B | ₩43.7B | ₩43.9B | ₩41.8B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| ABL Bio 298380.KS | $1.51B | -71% | -53% | -201% | 46.5× | n/a |
| LigaChem Biosciences 141080.KS | $1.48B | -72% | -55% | -324% | 17.0× | n/a |
| Aimed Bio 0009K0.KS | $778M | -61% | +228% | 34% | 13.8× | 10.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 298380.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.5% | -3.8% | 5th lowest of 21 |
| 6-month return | -71.3% | -8.4% | 2nd lowest of 21 |
| Distance from 52-week high | -86.0% | -38.1% | lowest of 21 |
| Revenue growth (TTM) | -53.0% | +10.1% | 3rd lowest of 20 |
| Operating margin | -201.0% | 11.0% | 4th lowest of 20 |
| EV / Sales | 46.5× | 3.8× | 3rd most expensive of 20 |
| ROIC minus cost of capital | -84.5 pp | -0.2 pp | 4th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | 46.5× | n/a | n/a |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | 3.5× | -4.9% | +0.2% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 1.4× | -6.1% | +1.9% |
| LigaChem Biosciences 141080.KS | South Korea | $1.48B | -72% | -55% | -324% | 17.0× | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.48B | +27% | +17% | 18% | 8.9× | 36.3% | +16.6% |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | 0.9× | -6.8% | +32.4% |
| Xiamen Kingdomway 002626.SZ | China | $1.45B | -3% | -3% | 11% | 3.1× | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.44B | +5% | +10% | 13% | 1.4× | -6.4% | +12.7% |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 2.5× | n/a | n/a |
| Mezzion Pharma 140410.KS | South Korea | $1.43B | -15% | +13% | -211% | 216.0× | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 4.5× | 6.0% | -4.3% |
| Voronoi 310210.KS | South Korea | $1.43B | -62% | -100% | -438,152% | 85,633.6× | n/a | n/a |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 2.0× | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.43B | +36% | +24% | 20% | 3.8× | 31.0% | +16.6% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 1.2× | -6.6% | -5.6% |
| Nippon Shinyaku 4516.T | Japan | $1.42B | -20% | +18% | 18% | 0.8× | -18.1% | +7.0% |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 5.2× | 12.8% | -14.0% |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 9.8× | 31.1% | -15.1% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 7.2× | n/a | n/a |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | 5.6× | 42.4% | +23.0% |